Compare PLSE & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | NVCR |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2015 |
| Metric | PLSE | NVCR |
|---|---|---|
| Price | $25.49 | $17.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $22.00 | ★ $28.08 |
| AVG Volume (30 Days) | 348.7K | ★ 1.8M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $840.00 | $7.72 |
| Revenue Next Year | $287.54 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $12.56 | $9.82 |
| 52 Week High | $27.98 | $20.05 |
| Indicator | PLSE | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 64.94 |
| Support Level | $17.58 | $12.48 |
| Resistance Level | $27.14 | $18.92 |
| Average True Range (ATR) | 1.79 | 0.83 |
| MACD | 0.28 | -0.11 |
| Stochastic Oscillator | 70.28 | 66.01 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.